TRCT
OTLK icon

Tower Research Capital (TRC)’s Outlook Therapeutics OTLK Stock Holding History

Tower Research Capital (TRC)’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.3K Buy
57,391
+42,586
+288% +$26.4K ﹤0.01% 2262
2026
Q1 		$3.05K Buy
14,805
+1,932
+15% +$835 ﹤0.01% 4374
2025
Q4 		$20.3K Buy
+12,873
New +$20.6K ﹤0.01% 3086
2025
Q3 		– Sell
-8,259
Closed -$13.2K – 5511
2025
Q2 		$13.2K Sell
8,259
-399
-5% -$636 ﹤0.01% 3870
2025
Q1 		$10.6K Buy
8,658
+2,270
+36% +$3.98K ﹤0.01% 3625
2024
Q4 		$12.1K Buy
6,388
+4,438
+228% +$18.3K ﹤0.01% 3652
2024
Q3 		$10.4K Sell
1,950
-425
-18% -$3.11K ﹤0.01% 3762
2024
Q2 		$17.5K Buy
2,375
+1,865
+366% +$15K ﹤0.01% 3834
2024
Q1 		$6.09K Sell
510
-638
-56% -$5.16K ﹤0.01% 4434
2023
Q4 		$9.04K Sell
1,148
-1,182
-51% -$9.99K ﹤0.01% 4443
2023
Q3 		$10.3K Buy
2,330
+2,099
+909% +$46.4K ﹤0.01% 4127
2023
Q2 		$8.04K Sell
231
-946
-80% -$25.8K ﹤0.01% 4481
2023
Q1 		$26K Buy
1,177
+796
+209% +$17.8K ﹤0.01% 3163
2022
Q4 		$8K Sell
381
-1,724
-82% -$37.5K ﹤0.01% 4434
2022
Q3 		$51K Buy
2,105
+1,298
+161% +$30.2K ﹤0.01% 3141
2022
Q2 		$16K Sell
807
-3,115
-79% -$89.6K ﹤0.01% 4014
2022
Q1 		$139K Buy
3,922
+2,724
+227% +$85.1K ﹤0.01% 1990
2021
Q4 		$33K Buy
1,198
+234
+24% +$8.35K ﹤0.01% 3136
2021
Q3 		$42K Buy
964
+874
+971% +$42.2K ﹤0.01% 3095
2021
Q2 		$4K Sell
90
-1,129
-93% -$52.4K ﹤0.01% 4828
2021
Q1 		$55K Buy
1,219
+881
+261% +$33.7K ﹤0.01% 3047
2020
Q4 		$9K Buy
+338
New +$7.06K ﹤0.01% 4393
2016
Q4 		– Sell
-4
Closed -$3K – 4241
2016
Q3 		$3K Hold
4
– – ﹤0.01% 2873
2016
Q2 		$2K Buy
+4
New +$2.39K ﹤0.01% 3936

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Tower Research Capital (TRC)'s OTLK Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Outlook Therapeutics (OTLK) stake by 288% in Q2 2026, buying an estimated $26.4K and bringing the position to 57,391 shares worth $91.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2262.

Tower Research Capital (TRC) first reported a position in OTLK in Q2 2016 and has held it in 24 quarters since. The position peaked at $139K in Q1 2022. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Tower Research Capital (TRC) held 57,391 shares of Outlook Therapeutics worth $91.3K as of Q2 2026.
  • Tower Research Capital (TRC) bought 42,586 Outlook Therapeutics shares in Q2 2026, an estimated $26.4K.
  • Outlook Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2262 holding.
  • Tower Research Capital (TRC) first reported a position in Outlook Therapeutics in Q2 2016 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Outlook Therapeutics position peaked at $139K in Q1 2022.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.